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Summary
Background Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder 
that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we 
present the ﬁ nal analysis of a prospective multicentre study by the European MSA Study Group to investigate the 
natural history of MSA.
Methods Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years. Vital status 
was ascertained 2 years after study completion. Disease progression was assessed using the uniﬁ ed MSA rating scale 
(UMSARS), a disease-speciﬁ c questionnaire that enables the semiquantitative rating of autonomic and motor 
impairment in patients with MSA. Additional rating methods were applied to grade global disease severity, autonomic 
symptoms, and quality of life. Survival was calculated using a Kaplan-Meier analysis and predictors were identiﬁ ed in 
a Cox regression model. Group diﬀ erences were analysed by parametric tests and non-parametric tests as appropriate. 
Sample size estimates were calculated using a paired two-group t test. 
Findings 141 patients with moderately severe disease fulﬁ lled the consensus criteria for MSA. Mean age at symptom 
onset was 56·2 (SD 8·4) years. Median survival from symptom onset as determined by Kaplan-Meier analysis was 
9·8 years (95% CI 8·1–11·4). The parkinsonian variant of MSA (hazard ratio [HR] 2·08, 95% CI 1·09–3·97; p=0·026) 
and incomplete bladder emptying (HR 2·10, 1·02–4·30; p=0·044) predicted shorter survival. 24-month progression 
rates of UMSARS activities of daily living, motor examination, and total scores were 49% (9·4 [SD 5·9]), 74% 
(12·9 [8·5]), and 57% (21·9 [11·9]), respectively, relative to baseline scores. Autonomic symptom scores progressed 
throughout the follow-up. Shorter symptom duration at baseline (OR 0·68, 0·5–0·9; p=0·006) and absent levodopa 
response (OR 3·4, 1·1–10·2; p=0·03) predicted rapid UMSARS progression. Sample size estimation showed that an 
interventional trial with 258 patients (129 per group) would be able to detect a 30% eﬀ ect size in 1-year UMSARS 
motor examination decline rates at 80% power.
Interpretation Our prospective dataset provides new insights into the evolution of MSA based on a follow-up period 
that exceeds that of previous studies. It also represents a useful resource for patient counselling and planning of 
multicentre trials.
Funding Fifth Framework Programme of the European Union, the Oesterreichische Nationalbank, and the Austrian 
Science Fund.
Introduction
Multiple system atrophy (MSA) is a rare but distinctive 
and fatal α-synucleinopathy characterised by autonomic 
failure, parkinsonism, cerebellar ataxia, and pyramidal 
signs in various combinations. These symptoms are the 
result of overlapping pathologies including striatonigral, 
olivopontocerebellar, and central autonomic degener-
ation.1,2 Two phenotypes can be distin guished clinically by 
the predominant motor symptom: the parkinsonian 
variant (MSA-P) and the cerebellar variant (MSA-C).3 
However, autonomic fea tures can predate motor 
impairment.4,5 Premotor MSA is increas ingly recognised 
as a cluster of symptoms in clud ing not only progressive 
autonomic failure, but also sleep disorders such as rapid 
eye movement sleep behaviour disorder, central sleep 
apnoea, and stridor.6
With two exceptions that we are aware of,7–9 the natural 
history of MSA has been addressed only in single-centre 
clinical stud ies.10,11 Additionally, disease progression and 
prognostic predictors have been investigated in 
retrospective clini co pathological series.4,12–16 These 
studies found shorter survival in patients with early 
autonomic failure13,15 and a more pronounced functional 
deterioration in patients with MSA-P than in patients 
with MSA-C.15 Rates of functional decline and their 
determinants were not established using validated 
disease-speciﬁ c rating scales.4,12–16 Recognising this 
unmet need, a consortium of dedicated MSA research 
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groups (European MSA Study Group [EMSA-SG]) 
established a large patient registry,17 developed and 
validated an MSA-speciﬁ c rating scale (uniﬁ ed MSA 
rating scale [UMSARS]),18 and launched a large 
prospective natural history study with 2 years of follow-
up. With this study we aimed to address the following 
objectives: to determine prospectively clinical predictors 
of disease progression; to validate the disease-speciﬁ c 
UMSARS18 longitudinally, thereby deriving rates of 
decline; to facilitate counselling of patients about 
disease stage (early or advanced disease) and milestones 
(such as falls or dysphagia); and to promote basic-
research driven19–22 clinical trial activity23,24 within EMSA-
SG or other related networks. Preliminary results in 
50 patients were previously reported.25 Here we present 
the ﬁ nal results of the full analysis.
Methods
Study design and patients
15 EMSA-SG centres participated in this prospective 
natural history study. Recruitment lasted from January, 
2003, to July, 2004. Study duration was 2 years with a 
follow-up every 6 months. Additionally, a vital status 
survey was done 2 years after the end of the study. 
Survival and UMSARS decline rates were predeﬁ ned 
primary outcome measures. In a post-hoc analysis of 
UMSARS items, important preterminal clinical mile-
stones as suggested by O’Sullivan and colleagues13 were 
probed. The study was approved by local ethics com-
mittees, and written informed consent was obtained 
from each patient.
All patients were interviewed and examined by board-
certiﬁ ed neurologists from the study group who had 
experience in movement disorders; patients with a 
clinical diagnosis of MSA as judged by these neurolo-
gists were enrolled in the present study. The following 
features were considered as exclusion criteria: onset 
under 30 years of age, family history of a movement 
disorder,   secondary cause of parkinsonism (by history 
or investigation), prominent slowing of vertical 
saccades, vertical supranuclear palsy (downward or 
upward gaze palsy), aphasia, alien limb syndrome, 
parietal dys function, generalised areﬂexia, and any 
condition which would make the patient, in the opinion 
of the treating investigator, unsuitable for an MSA 
natural history study. However, reasons to refrain from 
recruitment were not recorded systematically. The 
initial consensus criteria3 were subsequently applied to 
conﬁ ne the analysed cohort to patients with MSA. At 
each study visit the EMSA-SG minimal dataset26 was 
used to document basic clinical features and diagnostic 
procedures as well as the current medication. Moreover, 
validated rating instruments were applied during the 
follow-up examination by the in vestigator, patient, or 
caregiver, as appropriate. Causes of death, MRI 
ﬁ ndings, and results from post-mortem exam in ations 
were not systematically recorded.
Figure 1: Study ﬂ ow diagram
Data refer to non-interpolated case numbers. Thus, patients who had incomplete data at one assessment could be 
included again later. EMSA=European MSA Study Group. ADL=activities of daily living. ME=motor examination. 
UMSARS=uniﬁ ed MSA rating scale.
141 patients alive at baseline visit Data available for baseline visit
120 UMSARS Total
125 UMSARS ADL
124 UMSARS ME
 11 patients died   9 patients died
13 missing ADL and ME data
0 missing ADL data only
15 missing ME data only
130 patients alive at 6-month 
         follow-up
Data available for 6-month follow-up
   93 UMSARS Total
108 UMSARS AD
   93 UMSARS ME
11 patients died
23 lost to follow-up
11 patients died
18 lost to follow-up
26 missing ADL and ME data
  4 missing ADL data only
  8 missing ME data only
96 patients alive at 12-month 
       follow-up
Data available for 12-month follow-up
   54 UMSARS Total
   62 UMSARS ADL
   58 UMSARS ME
   5 patients died
25 lost to follow-up
  5 patients died
21 lost to follow-up
  8 missing ADL and ME data
0 missing ADL data only
12 missing ME data only
66 patients alive at 18-month 
       follow-up
Data available for 18-month follow-up
   46 UMSARS Total
   58 UMSARS ADL
   46 UMSARS ME
   7 patients died
10 lost to follow-up
   7 patients died
10 lost to follow-up
  2 missing ADL and ME data
0 missing ADL data only
  4 missing ME data only
224 patients registered in the EMSA patient registry 
         during enrolment period (January, 2003–July, 2004)
73 patients deemed ineligible by the investigator
151 patients recruited in EMSA natural history study
10 excluded because of 
misdiagnosis
10 patients misdiagnosed
11 missing ADL and ME at all
      follow-up visits
  5 missing ADL data only
  6 missing ME data only
49 patients alive at 24-month 
       follow-up
Data available for 24-month follow-up
   43 UMSARS Total
   47 UMSARS ADL
   43 UMSARS ME
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Symptom onset was deﬁ ned as the initial presentation 
of any motor symptom (ie, parkinsonism or cerebellar 
ataxia) or selected autonomic features including ortho-
static hypotension or neurogenic bladder disturbances 
(urge incontinence and incomplete bladder emptying). 
Absent levodopa response was deﬁ ned as no clinical 
improvement on chronic treatment as judged by the 
treating investigator.
Rating scales
Overall disease severity was assessed by the Hoehn and 
Yahr Parkinson’s disease staging scheme (range 1–5, 
with higher scores indicating greater impairment),27 
the Schwab and England activities of daily living scale 
(range 0–100, with lower scores reﬂ ecting greater disease 
burden),28 and a three-point global disability scale (mild, 
moderate, severe).18 We assessed severity of clinical 
features using a disease speciﬁ c rating scale (total 
UMSARS, with scores ranging from 0 to 104; higher 
scores indicate greater impairment) that includes 
autonomic symptoms (questions 9–12 of the UMSARS 
activities of daily living subscale [range 0–16]) and motor 
symptoms (questions 1–8 of the UMSARS activities of 
daily living subscale [range 0–32] and the UMSARS 
motor examination subscale, range 0–56), as well as their 
eﬀ ect on activities of daily life (UMSARS activities of daily 
living subscale, range 0–48). Probability of clinical 
milestone events was estimated in a post-hoc analysis of 
UMSARS items 2 (swallowing) and 8 (falling) of the 
activities of daily living subscale and items 2 (speech) and 
 Overall MSA-P MSA-C p 
N (%) 141 (100) 87 (61·7) 54 (38·3)  
Diagnostic certainty    0·351
Possible, n (%) 32 (22·7) 22 (25·3) 10 (18·5)
Probable, n (%) 109 (77·3) 65 (74·7) 44 (81·5)
Sex    0·929
Women, n (%) 62 (44) 38 (44) 24 (44)
Men, n (%) 79 (56) 49 (56) 30 (56)
Age     
Study entry, years 
(mean [SD])
62·1 (7·7) 62·6 (8·2) 61·3 (7·1) 0·367
Symptom onset, 
years (mean [SD])
56·2 (8·4) 56·8 (9·0) 55·4 (7·4) 0·378
Duration of 
symptoms at entry, 
years (mean [SD])
5·5 (3·8) 5·1 (3·7) 6·1 (3·9) 0·134
Global disability scale 
(mean [SD])
2·3 (0·7) 2·3 (0·7) 2·2 (0·7) 0·388
Mild, n (%) 17 (12·1) 9 (10·3) 8 (14·8)
Moderate, n (%) 60 (42·6) 33 (37·9) 27 (50)
Severe, n (%) 48 (34·0) 30 (34·5) 18 (33·3)
Missing values, 
n (%)
16 (11·3) 15 (17·2) 1 (1·9)
Schwab and England 
activities of daily 
living (mean [SD])
48·9 
(22·1)
46·0 
(22·2)
52·8 
(21·5)
0·088
Hoehn and Yahr 
(mean [SD])
3·7 (1·0) 3·7 (0·9) 3·8 (1·1) 0·431
Stage 0, n (%) 1 (0·7) 0 (0) 1 (1·9)
Stage 1, n (%) 2 (1·4) 0 (0) 2 (3·7)
Stage 2, n (%) 6 (4·3) 6 (6·9) 0 (0)
Stage 3, n (%) 46 (32·6) 30 (34·5) 16 (29·6)
Stage 4, n (%) 41 (29·1) 21 (24·1) 20 (37·0)
Stage 5, n (%) 32 (22·7) 19 (21·8) 13 (24·1)
Missing values, n (%) 13 (9·2) 11 (12·6) 2 (3·7)
(Continues on next page)
 Overall MSA-P MSA-C p 
(Continued from previous page)
Autonomic failure, 
n (%)
136 (96·5) 84 (96·6) 52 (96·3) 0·936
Urinary 
incontinence, n (%)
103 (73·0) 66 (75·9) 37 (68·5) 0·241
Orthostatic 
hypotension, n (%)
80 (56·7) 51 (58·6) 29 (53·7) 0·341
Incomplete bladder 
emptying, n (%)
72 (51·1) 49 (56·3) 23 (42·6) 0·538
Constipation, n (%) 82 (58·2) 52 (59·8) 30 (55·6) 0·145
Parkinsonism, n (%) 128 (90·8) 87 (100·0) 41 (75·9) 0·0001
Bradykinesia, n (%) 128 (90·8) 87 (100·0) 41 (75·9) 0·0002
Rigidity, n (%) 117 (83·0) 88 (100·0) 30 (55·6) <0·0001
Postural instability, 
n (%)
115 (81·6) 75 (86·2) 40 (74·1) 0·607
Postural tremor, 
n (%)
79 (56·0) 55 (63·2) 24 (44·4) 0·090
Rest tremor, n (%) 50 (35·5) 35 (40·2) 15 (27·8) 0·243
Gait freezing, n (%) 56 (39·7) 45 (51·7) 11 (20·4) <0·0001
Levodopa treatment <0·0001
Yes, n (%) 91 (64·5) 71 (81·6) 20 (37·0)
No, n (%) 44 (31·2) 12 (13·8) 32 (59·3)
Unknown, n (%) 6 (4·3) 4 (4·6) 2 (3·7)
Dopamine agonist 
treatment
0·012
Yes, n (%) 31 (22·0) 24 (27·6) 7 (13·0)
No, n (%) 91 (64·5) 47 (54·0) 44 (81·5)
Unknown, n (%) 19 (13·5) 16 (18·4) 3 (5·6)
Levodopa response     
Beneﬁ cial response, 
n (%)
44 (31·2) 37 (42·5) 7 (13·0) 0·086
Response duration, 
years (mean [SD])
3·5 (2·7) 3·5 (2·7) 3·3 (2·7) 0·908
Cerebellar symptoms, 
n (%)
101 (71·6) 47 (54·0) 54 (100·0) <0·0001
Gait ataxia, n (%) 87 (61·7) 35 (40·2) 52 (96·3) <0·0001
Limb ataxia, n (%) 79 (56·0) 31 (35·6) 48 (88·9) <0·0001
Ataxic dysarthria, 
n (%)
77 (54·6) 29 (33·3) 48 (88·9) <0·0001
Pyramidal 
involvement, n (%)
70 (49·6) 39 (44·8) 31 (57·4) 0·146
Babinski sign, n (%) 38 (27·0) 21 (24·1) 17 (31·5) 0·274
Hyper-reﬂ exia, n (%) 58 (41·1) 31 (35·6) 27 (50·0) 0·076
Dystonia, n (%) 43 (30·5) 28 (32·2) 15 (27·8) 0·403
Table 1: Population characteristics at baseline 
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14 (gait) of the motor examination subscale. Health-
related quality of life was assessed by the medical study 
short form (SF-36)29 and the ﬁ ve-dimensional EuroQoL 
(EQ-5D).30
Autonomic failure was assessed with the composite 
autonomic symptom scale (COMPASS)31 as well as the 
COMPASS change scale31 in a sub-protocol of the present 
study that was done in ﬁ ve EMSA-SG sites. The 6-month 
data for COMPASS decline rates have partly been 
published else where.32 Here, we present the 24-month 
follow-up data.
Statistical analysis
Hardcopies of case report forms were returned to the 
study secretariat to ensure data quality. Any shortcoming 
was subsequently discussed by investigators through 
email conversations, telephone calls, and at annual 
EMSA-SG meetings. Data were entered into an ACCESS 
Database (Microsoft, Redmond, WA, USA) and analysed 
with SPSS 19.0 (SPSS, Chicago, IL, USA). Statistical 
analysis of disease progression was done for all patients 
for whom data for two UMSARS motor examination and 
activities of daily life assessments were available. Missing 
values of the two UMSARS subscales during the follow-
up were estimated using linear inter polation of 
neighbouring measurements. Missing values of baseline 
and ultimate measurements in patients known to be 
alive were analogously extrapolated by using two 
succeeding or preceding measurements. The ﬁ nal rating 
score was calculated as sum of the two UMSARS subscale 
measurements per patient.
To validate the interpolation approach we undertook 
two sensitivity analyses. First, we did a complete-case 
per-protocol analysis to validate the results received by 
the linear interpolation procedure, and we compared 
observed (non-missing) and imputed values at each 
timepoint with the t test. Cases with missing obser-
vations, where the missing-at-random assumption came 
into question, were reviewed manually. Second, we 
estimated missing values of potential predicting vari-
ables for MSA progression using a fully conditional 
speciﬁ cation33 multiple impu tation procedure assuming 
that those values were missing at random. The fully 
conditional speciﬁ cation procedure ﬁ rst sub stituted 
missing data of potential predictors by plausible values 
using an iterative stochastic algorithm, which results in 
ten multiple complemented replications of the original 
dataset. These datasets were then separately analysed 
with a logistic-regression model to obtain the estimates 
of interest. The estimates from these imputed datasets 
are then combined (pooled) into one overall estimate 
and variance, and then compared with the original 
dataset.
Progression of scores was deﬁ ned as mean diﬀ erence 
between baseline and follow-up values. Annualised 
slopes of change were presented as comparison of 
baseline values and the last follow-up examination 
available and expressed as score change per year. The 
following formula was used:
Figure 2: Kaplan-Meier survival plot
Overall survival analysis from symptom onset (A). Survival analysis stratiﬁ ed by phenotype (B). 
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Gaussian distribution was conﬁ rmed by visual analysis 
of the Q-Q plots and the Kolmogorov–Smirnov test. 
With respect to the two distinct motor variants, two 
subgroups were formed. Time eﬀ ects were analysed by 
repeated measures ANOVA. Group diﬀ erences of 
normally distributed data were analysed by parametric 
tests (repeated measures ANOVA or Student’s t test as 
applicable), non-Gaussian distributed variables by non-
parametric tests (Kruskal–Wallis one-way ANOVA by 
ranks or Mann–Whitney U test as applicable), and 
distributional diﬀ erences by the Pearson’s χ² test for 
independence. Logistic regression analysis was used to 
determine predictors of fast or slow motor progression. 
Consistent with Seppi and colleagues,10 the cutoﬀ  point 
between fast and slow progression was deﬁ ned by the 
median value of annualised progression rates.
Survival from symptom onset was calculated using 
Kaplan-Meier analysis; covariates were compared with 
the log-rank test and Cox regression analysis. To reduce 
the number of censored observations, we surveyed vital 
status 24 months after study end. Patients lost to follow-
up were censored at the last known date alive.
Clinical milestones of preterminal disease that were 
derived from previous clinicopathological studies13 were 
analysed by retrospective analysis of the UMSARS 
questionnaires. Each of the four clinical milestones were 
modelled as binary response variables during diﬀ erent 
time intervals (symptom onset to baseline visit, during 
ﬁ rst year of follow-up, and during second year of follow-
up) applying a complementary log-log link function to 
estimate the probability of experiencing one of them.34 
Events were deﬁ ned as progression to the maximum score 
in the four UMSARS items (feeding by nasogastric tube or 
gastrostomy because of severe dysphagia, falls at least once 
a day, unintelligible speech, and the inability to walk).
Sample size estimates were done using two-group 
t test, accepting a two-sided type one error of 5%. The 
signiﬁcance level was set at p<0·05.
Role of the funding source
Funds from the European Union supported the 
development of the study design, study conduct (patient 
recruitment, study visits), database development, and 
data collection. The Oesterreichische Nationalbank and 
Austrian Science Fund supported data analysis, data 
interpretation, and drafting of the manuscript. The 
sponsors had no role in the study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
151 consecutive eligible patients were initially recruited at 
the participating centres (ﬁ gure 1). During the study 
period, the clinical diagnosis was revised in ﬁ ve cases, 
and further eﬀ orts to retrieve survival information in the 
post-study survival survey revealed another ﬁ ve 
misdiagnosed patients. These patients were reclassiﬁ ed 
during follow-up on the basis of changes in their clinical 
presentation. 79 (56%) of the remaining 141 patients were 
men and 62 (44%) were women. Mean age at symptom 
onset was 56·2 (SD 8·4) years; mean duration of 
symptoms at baseline was 5·5 (SD 3·8) years (table 1). 
These ﬁ ndings were not signiﬁ cantly diﬀ erent between 
MSA-C and MSA-P patients. According to consensus 
criteria,3 62% of the patients were classiﬁ ed as having 
MSA-P and 38% as having MSA-C. 32 patients (23%) 
fulﬁ lled criteria for possible MSA (possible MSA-P 25%, 
possible MSA-C 19%) and 109 (77%) for probable MSA 
(probable MSA-P 75%, probable MSA-C 81%) according 
to the initial consensus criteria.3 Degree of diagnostic 
certainty did not diﬀ er between MSA-P and MSA-C 
(p=0·351). There were no sex diﬀ erences between the two 
motor presentations (p=0·929).
47 (54%) patients with MSA-P had cerebellar symptoms, 
and 41 (76%) patients with MSA-C frequently showed 
parkinsonism. Symptoms of autonomic failure were 
present in most of the patients studied (136 [96%]). Urinary 
symptoms (124 patients [88%]) including urinary 
incontinence (103 [73%]) and incomplete bladder emptying 
(72 [51%]) combined were  more common than orthostatic 
hypotension (80 [57%]). Irregular postural tremor of the 
outstretched arms was more common than resting tremor 
(56% vs 35%). A beneﬁ cial response to levodopa was 
reported in 31% lasting for a mean period of 3·5 years. 
Some of the patients with a beneﬁ cial levodopa response 
(44 patients, table 1) had motor complications, with 
 From symptom onset to baseline visit During ﬁ rst year of follow-up During second year of follow-up
Number of events/
patients at risk
Estimated probability 
(95% CI) of an event*
Number of events/
patients at risk
Estimated probability 
(95% CI) of an event*
Number of events/
patients at risk
Estimated probability 
(95% CI) of an event*
Falls at least once a day 34/105 23% (13·3– 40·0%)† 11/42 21% (10·7–40·2%)† 8/16 45% (20·4–98·4%)‡
Feeding by nasogastric tube or gastrostomy 3/83 3% (0·7–12·9%)† 7/51 13% (4·5–38·0%)§ 2/29 6% (1·4–30·0%)¶
Unintelligible speech 12/117 7% (3·2–15·9%)† 11/59 13% (6·0–28·7%)† 5/26 15% (5·3–39·9%)§
Wheelchair dependency 17/123 9% (4·3–18·4%)† 11/59 13% (6·3–28·3%)† 5/25 14% (5·2–37·9%)||
*Estimated probabilities of an event ﬁ tted by an interval-censored survival model applying a complementary log-log link function. p values are Wald-χ2. †p<0·0001. ‡p=0·046 . §p=0·0002. ¶p=0·0005. 
||p=0·0001.
Table 2: Estimated probability of clinical milestones
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wearing-oﬀ  ﬂ uctuations (ten patients [23%]) and oﬀ -
dystonia (nine [20%]) being the most common. On-oﬀ  
motor ﬂ uctu ations (six patients [14%]) and peak-dose 
dyskinesias (ﬁ ve [11%]) were less frequently present. 
Further baseline characteristics of the study population are 
shown in table 1. Dynamics of characteristic motor features 
through out the study period are listed in the appendix.
During the study period, including a stand-alone vital 
status survey 2 years after study end, we recorded 61 deaths 
in the study population of 141 patients. Neuropathological 
assessment conﬁ rmed the clinical diagnosis in two 
patients who underwent post-mortem veriﬁ cation. 
Overall, median survival from symptom onset as 
determined by Kaplan-Meier analysis was 9·8 years 
(95% CI 8·1–11·4). Uni variable regression analysis 
adjusted for sex and age at symptom onset identiﬁ ed a 
diagnosis of MSA-P (hazard ratio [HR] 1·84, 95% CI 
1·05–3·25, p=0·034), presence of urinary incontinence 
(2·45, 1·19–5·04, p=0·015), presence of incomplete 
bladder emptying (2·16, 1·08–4·34, p=0·030), presence of 
pyramidal signs (1·60, 0·92–2·79, p=0·099), presence of 
hyper-reﬂ exia (2·62, 0·94–2·81, p=0·085), and higher 
baseline scores for the UMSARS activities of daily living 
subscale (1·04, 1·01–1·07, p=0·021) as predictors of 
shorter survival at p<0·1 (the cutoﬀ  criterion). Hyper-
reﬂ exia was excluded because of colinearity with pyramidal 
signs. All parameters with a p<0·1 in the univariable 
regression analysis were entered in a Cox regression 
model adjusted for age at symptom onset and sex, which 
identiﬁ ed a diagnosis of MSA-P (HR 2·08, 95% CI 
1·09–3·97, p=0·026, ﬁ gure 2) and the presence of 
incomplete bladder emptying (2·10, 1·02–4·30, p=0·044) 
as the strongest predictors of shorter survival.
An interval-censored survival model was applied to 
patients with milestone events (complete loss of function) 
at the beginning or during the study period. The estimated 
probabilities of clinical milestone events including falls at 
least once a day, wheelchair dependency, nasogastric tube 
placement or gastrostomy, and unintelligible speech are 
shown in table 2.
Progression rates are shown in table 3 and ﬁ gure 3. 
First year progression rate for the UMSARS activities of 
daily living subscale was 32·3% (mean 6·5 points 
[SD 6·0]) and for the motor examination subscale was 
44·9% (8·2 points [7·0]), relative to base line. In the 
second year, we recorded attenuated UMSARS decline 
rates of 11·2% (2·9 points [SD 3·4]) on the activities of 
daily living subscale and 17·2% (5·0 points [5·4]) on the 
motor subscale, relative to 12-month scores. The repeated 
measures ANOVA involving UMSARS meas urements at 
baseline, after 1 year, and at the end of the study yielded a 
signiﬁ cant time eﬀ ect (p<0·0001) including a second-
order term (p=0·002) conﬁ rming the second year 
attenuation. Overall 2-year progression rate for UMSARS 
activities of daily living, motor examination, and total 
scores were 49·0% (9·4 [SD 5·9]), 74·2% (12·9 [8·5]), and 
57·3% (21·9 [11·9]), respectively, relative to baseline. The 
sensitivity com plete-case per protocol analysis (appendix) 
conﬁ rmed the ﬁ ndings of the linear interpolation 
analysis. Additionally, we did not ﬁ nd any signiﬁ cant 
diﬀ erences between observed (non-missing) and imputed 
values at each timepoint. In a univariable binary logistic 
regression analysis, symptom duration at baseline (OR1 year 
[OR for each additional year since symptom onset] 0·81, 
95% CI 0·71–0·93, p=0·003), the absence of MSA-P (OR 
0·51, 0·24–1·08, p=0·077), a beneﬁ cial levo dopa response 
Total Activities of 
daily living
Motor 
examination
Baseline
N 126 127 129
Score, mean (SD) 51·2 (17) 25·2 (8·8) 25·9 (9)
Score, median 49 25 25 
95% CI 48·2–54·2 23·7–26·8 24·3–27·5
6-month follow-up 
N 103 111 105
Score, mean (SD) 59·3 (17·7) 28·4 (8·9) 30·6 (9·5)
Score, median 59 28 29 
95% CI 55·8–62·8 26·7–30 28·8–32·5
Score diﬀ erence, mean (SD) 9·2 (8·9) 3·9 (4·6) 5·3 (5·6)
Score diﬀ erence, median 8 4 4 
95% CI 7·5–11 3–4·8 4·2–6·4
Mean percent change 22% 19·1% 28·2%
12-month follow-up
N 85 87 87
Score, mean (SD) 64·7 (18·8) 30·9 (9·5) 33·7 (10)
Score, median 64 31 33
95% CI 60·6–68·7 28·9–32·9 31·6–35·8
Score diﬀ erence, mean (SD) 14·6 (11·8) 6·5 (6) 8·2 (7)
Score diﬀ erence, median 12·5 5·5 7
95% CI 12·1–17·2 5·2–7·8 6·7–9·7
Mean percent change 36·4% 32·3% 44·9%
18-month follow-up
N 64 65 64
Score, mean (SD) 69·5 (17·1) 33·3 (8·4 ) 36·2 (9·9)
Score, median 68·5 32·3 36
95% CI 65·2–73·7 31·3–35·4 33·7–38·6
Score diﬀ erence, mean (SD) 19·9 (12·2) 8·6 (5·9) 11·4 (7·7)
Score diﬀ erence, median 17·5 8 10
95% CI 16·9–22·9 7·1–10·1 9·5–13·3
Mean percent change 51·2% 44·3% 63·3%
24-month follow-up
N 49 49 49
Score, mean (SD) 69·5 (17·1) 33·3 (8·2) 36·6 (11)
Score, median 68 33 37
95% CI 64·6–74·5 31–35·7 33·4–39·7
Score diﬀ erence, mean (SD) 21·9 (11·9) 9·4 (5·9) 12·9 (8·5)
Score diﬀ erence, median 20 9 12
95% CI 18·5–25·3 7·7–11·1 10·5–15·3
Mean percent change 57·3% 49% 74·2%
Table 3: UMSARS score decline rates comparing follow-up versus 
baseline values
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(2·52, 1·03–6·18, p=0·044), and the pres ence of sleep 
disturbances (1·92, 0·91–4·09, p=0·09) were found to be 
associated with slower disease progression (annualised 
progression rates below the median value) at p<0·1.
These parameters were entered in a multivariable 
binary logistic regression model adjusted for UMSARS 
baseline score and age at symptom onset, revealing that 
symptom duration at baseline (OR1 year 0·68, 95% CI 
0·52–0·90, p=0·006) and an absent levodopa response 
(3·38, 1·12–10·22, p=0·03) were associated with rapid 
disease progression. Data for quality of life in patients 
with MSA are shown in the appendix. Subgroup analysis 
of 24-month follow-up data of the COMPASS change 
scale showed a continuous increase of self-perceived 
autonomic symptoms (appendix).
Required sample sizes for interventional trials with 
1-year follow-up were estimated based on 12-month 
UMSARS total, motor examination, and activity decline 
rates. Estimated sample sizes per group to achieve 80% 
and 90% power with eﬀ ect sizes ranging from 20% to 
100% are shown in ﬁ gure 4. For example, an inter-
ventional trial with 258 patients (129 per group) would be 
able to detect a 30% reduction in annual UMSARS motor 
examination decline rates at 80% power.
Discussion
This multicentre prospective natural history study in a 
European cohort of MSA patients showed a reduced 
median survival of 9·8 years and rapid disease progression 
as determined by the UMSARS rating scale during an 
Figure 3: Uniﬁ ed MSA rating scale progression
Box plot of uniﬁ ed MSA rating scale (UMSARS) scores throughout the study period (A). Annualised progression rates stratiﬁ ed by categories of symptom duration (B). Annualised progression rates 
split by present or absent levodopa response (C). Red=UMSARS total. Green=UMSARS activities of daily living. Blue=UMSARS motor examination.
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extended 24-month follow-up period. MSA-P and urinary 
retention were associated with poor survival. Accelerated 
UMSARS progression was predicted by shorter symptom 
duration at baseline and an absent levodopa response. 
The clinical presentation of the present series corrob-
orates: that MSA is a progressive and fatal disorder; that 
MSA-P is more common than MSA-C in Europe; that the 
motor disorder is often mixed, with cerebellar features in 
MSA-P and parkin sonian features in MSA-C; that MSA-P 
can mimic Parkinson’s disease-like features, including a 
sustained levo dopa response and levodopa-induced 
motor complica tions such as ﬂ uctuations and peak-dose 
dyskinesias, which could result in invasive therapies 
such as fetal mesencephalic grafts35 or deep brain 
stimulation with short-lived or absent beneﬁ t;36–41 and that 
autonomic failure is a characteristic and common feature 
of both MSA motor subtypes. These observations are 
consistent with previously published cohorts.4,7,15–17,42 
However, most of these studies are limited by short 
follow-up periods and small case numbers.
The amount of progression is below the previously 
published intermediate analysis in a smaller subset of 
the present cohort.25 However, the present progression 
rates exceed previous observations by May and col-
leagues,9 who reported an increase of 17·2% within 
12 months of follow-up, by roughly two-fold. This 
diﬀ erence could be caused by more rapid decline early in 
the disease in the EMSA-SG cohort, reﬂ ecting a mixed 
study population of possible and probable cases with 
more rapid loss of greater baseline function during the 
ﬁ rst year, whereas the cohort of the North American 
study9 exclusively involved probable (ie, more advanced) 
MSA cases. This interpretation is further supported by 
attenuated pro gression rates in the second year of follow-
up of the EMSA-SG cohort. Moreover, the present 
UMSARS decline rates are similar in magnitude to those 
for the united Parkinson’s disease rating scale reported 
by Seppi and colleagues,10 showing an annual increase of 
28·3% compared with baseline. A recent publication 
reported clinical progression using the Parkinson plus 
scale.8 Although direct comparison of the two scales is 
not possible, the ratio between annual slope of change 
and baseline score was similar in both studies. In 
summary, the variation in scale decline rates is likely to 
reﬂ ect both disease-related and scale-related factors. The 
rapid deterioration as shown by the UMSARS scores in 
our study was also mirrored by decline rates in both the 
Hoehn and Yahr scale and the Schwab and England 
activities of daily living scale. Remarkably, systolic blood 
pressure drop, as measured by part III of UMSARS, did 
not change signiﬁ cantly over time (data not shown), 
possibly as a result of adaptations in antiorthostatic 
hypotension therapy that were incompletely recorded. By 
contrast, COMPASS change scale scores that determine 
subjective impairment resulting from autonomic failure 
including orthostatic hypotension increased during 
follow-up in the present study. Mis match between the 
objective presence of orthostatic hypotension and 
subjective impairment has long been recognised. In 
general, our COMPASS CSS data conﬁ rm previous 
studies,43,44 including a preliminary 6-month follow-up 
report from the EMSA-SG32 demonstrating that MSA 
represents a progressive disorder that includes both 
autonomic and motor domains.
Shorter duration from symptom onset at baseline and 
an unsatisfactory levodopa response were shown to be 
the strongest predictors of a rapidly progressive disease 
course in the present study. These ﬁ ndings suggest that 
decline is more rapid in patients with greater functional 
reserve at baseline.25,45,46
In a previous clinicopathological study,13 four clinical 
milestones of advanced MSA were identiﬁ ed. In the 
current study, we estimated the probability of developing 
Panel: Research in context
Systematic review
We searched PubMed with the following search terms 
[(MSA OR “multiple system atrophy”) AND (progression OR 
survival)] for reports published before Oct 31, 2012. Only 
peer-reviewed, English language reports were considered. We 
included natural history studies reporting survival or disease 
progression as determined by semiquantitative rating scales. 
In our search we identiﬁ ed 11 observational studies.4,7–12,14–16,25
Interpretation
The natural history of MSA is still poorly understood. Our 
current knowledge is limited by the study design of 
published work, which includes retrospective case series 
with incomplete recordings of clinical features and 
single-centre studies that are limited by case numbers and 
only 12-month follow-up. The only multicentre prospective 
study we found7,8 used a non-speciﬁ c Parkinson plus scale 
that included features poorly reﬂ ective of MSA. The present 
multicentre study is the ﬁ rst natural history study that 
analyses survival and prognostic predictors in a large 
homogeneous cohort of European patients with MSA. It 
further reports semiquantitative decline rates using 
UMSARS, the only validated disease-speciﬁ c rating scale 
available. Our ﬁ ndings suggest that disease progression 
slows down in the second year of follow-up, which is 
important to consider when embarking on therapeutic 
trials. We also provide the ﬁ rst evidence in a prospective 
European MSA cohort that baseline parkinsonism and 
neurogenic bladder disturbance are linked to poor survival. 
Further, a shorter baseline symptom duration and absent 
levodopa response proved to be independent predictors of 
faster UMSARS progression. These insights have important 
implications for patient counselling and planning of drug 
trials. Finally, our prospective dataset enables sample size 
calculations for future interventional trials. The reported 
example shows that MSA trials require large cohorts that 
can be generated only in a multicentre set-up based on 
international networks such as EMSA-SG. 
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these milestones by retrospective analysis of selected 
UMSARS items and found that the likelihood of falling 
at least once a day increased with follow-up, particularly 
during the second year of follow-up. The probability of 
reaching the other milestones remained similar between 
years 1 and 2.
Previous studies indicate substantial impairment of 
health-related quality of life rating scales in early 
MSA.47–50 Thus far, little was known about the 
progression of these scales over time. As expected, EQ-
5D scores were already impaired at baseline. 
Nonetheless, a further decline in quality of life was 
observed in three out of ﬁ ve EQ-5D dimensions 
including mobility, self-care, and usual activities. 
Comparably, SF-36 items—particularly those requiring 
preserved motor function—showed pro gression to 
more severe impairment (appendix). The continuous 
clinical deterioration, indicated by the UMSARS motor 
and activities of daily living scores, supports the ﬁ ndings 
of May and colleagues,9 who state that UMSARS could 
serve as a favourable and disease-speciﬁ c outcome 
measure in interventional trials. The number of patients 
with MSA we estimate to be needed was substantially 
lower than those in the reports by May and colleagues9 
and Payan and colleagues,8 highlighting diﬀ erences of 
patient cohorts and score variabilities.
Our study has some limitations. The patients were all 
drawn from highly specialised outpatient clinics lacking 
the random distribution of prospective population-
based study designs. Moreover, restriction of data 
analysis to patients fulﬁ lling diagnostic criteria resulted 
in a selection of patients with advanced MSA; thus, 
mild disease stages might be under-represented in the 
present study. 2 years of clinical follow-up might also 
be too short to identify the overall progression and 
prognosis of MSA. Patients were assembled at a mean 
(SD) symptom duration of 5·5 (3·8) years, indicating 
that 16·7% of patients had MSA-related symptoms for 
over 8 years. These ﬁ ndings suggest that the current 
study should not be interpreted as an inception-type 
cohort study. Thus, very early deaths—those happening 
within a few years of symptom onset, which are likely 
to be the more severe cases—might be under-
represented. Patients were assessed on regular therapy; 
consequently, treatment eﬀ ects, although unlikely, 
cannot be excluded. In the absence of post-mortem 
veriﬁ cation, misdiagnosis in some of the clinically 
diagnosed patients might occur. Likewise, MRI ﬁ ndings 
and causes of death were not predeﬁ ned outcomes and, 
thus, were not systematically recorded, restricting 
conclusions drawn from the latter investigations. 
Attrition rates were considerable in our study. This was 
largely caused by death occurring during the study 
period and the inability of patients to attend study visits, 
reﬂ ecting the major challenge of avoiding dropout in 
prospective long-term MSA trials. Conse quently, 
progression rates could have been aﬀ ected by dropout 
of patients. Despite these limitations, this academically 
driven natural history study, involving 15 highly 
experienced study centres, deﬁ nes the spectrum 
of disease courses in European patients with MSA. Our 
data suggest that both mild and severe forms of 
MSA exist. Future clinicopathological studies are 
needed to determine whether the neuropathological 
lesion dis tribution, load, and type diﬀ er in patients. 
Our study is also the ﬁ rst that we know of to 
prospectively apply UMSARS, a carefully validated 
rating scale, longitudinally over a period of 2 years in a 
large cohort. The observed clinical decline rates will 
facilitate planning of future interventional trials in 
patients with MSA.
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